TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00937872
Drug: 250 mg SRT2104 Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 10 mL oral dose of 250 mg SRT2104 delivered as a suspension formulation.
Study: NCT02225756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration for a short time of placebo
Study: NCT03013556
Drug: Group A, TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF for 96 weeks
Study: NCT03560531
Drug: ZN-c5
Normalized name: dipentaerythrityl hexa C5-10 acid esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZN-c5 is a study drug
Study: NCT03011307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: spinal injection of placebo
Study: NCT04628676
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine is added to the irrigation fluid used in arthroscopic shoulder surgery.
Study: NCT00484939
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Capecitabine was supplied as tablets.
Study: NCT00745290
Drug: SKY0402
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg SKY0402 (study drug).
Study: NCT03014323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 capsule twice a day for 4 weeks
Study: NCT04087187
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will be given AZD5718 Dose A tablet once daily
Study: NCT04087187
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given AZD5718 Dose B tablet once daily
Study: NCT01067222
Drug: BF2.649
Approvals — FDA: no, EMA: no, PMDA: no
Description: BF2.649 oral capsules at 10 or 20 or 40 mg per day
Study: NCT01067222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsules, 4 capsules per day
Study: NCT01344187
Drug: placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0% riboflavin ophthalmic solution
Study: NCT02404285
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
Study: NCT02963337
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil PCA will be used to deliver intravenous drug boluses from 20 to 40 micrograms per 2 min lockout interval.
Study: NCT02963337
Drug: combined spinal-epidural analgesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled epidural analgesia will be used to deliver epidural boluses of 6-10 ml of 0,1% bupivacaine with 2 micrograms of fentanyl per ml per 15 min lockout interval.
Study: NCT01060904
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m2 IV every 2 weeks
Study: NCT02556333
Drug: FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir. This trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part of a salvage antiretroviral regimen for HIV-1-infected adults and adolescents (greater than or equal to 14 years) who experienced virologic failure.
Study: NCT05096143
Drug: ACEi/ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who were prescribed with Angiotensin-converting enzyme inhibitors/Angiotensin II receptor antagonists (ACEi/ARB)
Study: NCT00749788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets, oral, 30 minutes after the start of the morning meal
Study: NCT02467569
Drug: Hemay020
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04780854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the placebo group will be administered metformin free tablet as placebo twice daily
Study: NCT00990496
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2
Study: NCT00901758
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL
Study: NCT00713336
Drug: ZD4054
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD4054 10mg Tablet
Study: NCT00713336
Drug: ZD4054 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets
Study: NCT00713336
Drug: ZD4054 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets
Study: NCT00713336
Drug: ZD4054
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg tablet
Study: NCT00713336
Drug: ZD4054
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg tablet
Study: NCT03404479
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For 12 weeks, administered twice a day by oral.
Study: NCT03492255
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in both EUROLUPUS group and CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg/biweekly)
Study: NCT00708942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppository, for 3-7 hours application
Study: NCT00708942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment for 5 hours application
Study: NCT00988507
Drug: Ferroquine (SSR97193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT00988507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT04835025
Drug: PD-1/PD-L1 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: In non-small cell lung cancer, patients with brain metastases received radiotherapy for brain lesions and immunotherapy (including sequential and concurrent model). Those patients would enter the trial group; After patients experiencing PD in this group, follow-up treatment until tumor progression again or death
Study: NCT02443012
Drug: Topical Gutt Nepafenac 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Nepafenac as an adjunct to focal/grid laser
Study: NCT03631901
Drug: oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both melatonin and diazepam were given only during the febrile illness.
Study: NCT02540460
Drug: LCB01-0371 800mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCB01-0371 800mg
Study: NCT02540460
Drug: LCB01-0371 800mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCB01-0371 800mg BID
Study: NCT02540460
Drug: LCB01-0371 1200mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCB01-0371 1200mg BID
Study: NCT02540460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03341832
Drug: NVP-1203-R
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dose for 7 days
Study: NCT03341832
Drug: NVP-1203 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dose for 7 days
Study: NCT03341832
Drug: NVP-1203-R placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dose for 7 days
Study: NCT00239707
Drug: GIP
Normalized name: GIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-time 20 ng/kg/min infusion over 3 hours
Study: NCT00239707
Drug: Modified GIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-time infusion over 3 hours; dose to maintain desired biological effect of below 140 mg/dl
Study: NCT00239707
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: one-time infusion over 3 hours
Study: NCT03226431
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ARINA-1 (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
Study: NCT02691299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
Study: NCT01769040
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03730714
Drug: Local Anesthetic, Epinephrine and Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
Study: NCT03730714
Drug: Local Anesthetic, Epinephrine, Morphine and Surgicel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgicel soaked with mixture of: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
Study: NCT03730714
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline 0.9% to soak the surgicel according to the planned technique
Study: NCT03281954
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + placebo IV Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose.
Study: NCT00056030
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00056030
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00393991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
Study: NCT00545857
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of pioglitazone vs. placebo on the outcome of type 1 diabetes mellitus
Study: NCT00969163
Drug: testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks
Study: NCT00969163
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal placebo gel for 6 weeks
Study: NCT04178928
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: investigate the effect of replacement therapy with levothyroxine on cardiovascular risk factors in children with SCH.
Study: NCT01144416
Drug: Placebo for SCH 900962
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied as a pre-filled syringe containing an identical solution when~compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall.
Study: NCT01144416
Drug: Placebo for recFSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.
Study: NCT00440492
Drug: PLA-695
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05620056
Drug: chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs
Approvals — FDA: no, EMA: no, PMDA: no
Description: medication (i.e., chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs ) exposure through the pregnancy life course
Study: NCT00124072
Drug: Simvastatin 20 mg daily
Normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20 mg tablet once daily
Study: NCT00124072
Drug: Simvastatin 80 mg daily
Normalized name: simvastatin 80 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 80 mg tablet once daily
Study: NCT00124072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vitamin B12/folic acid tablet once daily
Study: NCT00092820
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02108756
Drug: Panmeilu
Approvals — FDA: no, EMA: no, PMDA: no
Description: An injection Panmeilu (80 mg) + 1 branch placebo, Bid;
Study: NCT01001767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04115774
Drug: bisphosphonates
Normalized name: Bisphosphonates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Since this is an observational study, the investigators collect general information on bisphosphonates treatment/impact
Study: NCT00873821
Drug: MK-0941
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 (in house): MK-0941 twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. The starting dose on Day 1 was 10 mg tablets twice daily and titrated to a maximum dose of 60 mg twice daily through Day 9. The Day 9 dose was maintained throughout Day 13. Part 2 (at home): participants continued treatment for an additional 14 days with MK-0941 60 mg tablets (or maximum dose achieved in Part 1) twice daily, before meals with 240 mL of water.
Study: NCT00873821
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 (in house): placebo twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. Part 2 (at home): participants continued treatment for an additional 14 days with placebo twice daily, before meals with 240 mL of water.
Study: NCT02732483
Drug: Endo-Clot(TM)
Normalized name: 2-acetoxy-1, 8-cineole, (+)-endo-
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients agreed in this study, bleeding control will going to be done with Endo-Clot(TM)
Study: NCT02452762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02637700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between placebo (saline 0.9%) and intravenous immunoglobulin.
Study: NCT03253887
Drug: Ethanol-lock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group received daily alcohol 70% (ethanol-lock) received intraluminal ethanol at a volume sufficient to fill the catheter lumen, ranged from 0.1 to 0.3 ml, with the volume being previously established. ELT was maintained for two full hours in each catheter lumen, with the lumen remaining locked during this period. The same procedure was then carried out with the other lumen. Prior to and following ELT, flushing was performed using 5-10 ml of 0.9% saline solution.
Study: NCT01121380
Drug: 1021
Normalized name: BARRIER,SENSURA COLOPLAST #11021
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1021
Study: NCT01238692
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to both arms will receive oral LBH589, once-a-day, at a dose of 30 mg/day, on a three times-a-week (Monday, Wednesday and Friday) schedule as part of a 3 week (21 day) treatment cycle. Day one of each cycle will be on a Monday.
Study: NCT02902185
Drug: ART plus Chidamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
Study: NCT02902185
Drug: ART plus Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
Study: NCT01985581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01985581
Drug: Stimulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)
Study: NCT02338960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02981342
Drug: LY3023414
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02981342
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT01629368
Drug: RO4917523
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of RO4917523
Study: NCT03502850
Drug: ASK120067
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients take ASK120067 orally once per day at 40,80,160,240,320,480mg
Study: NCT01614990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (Powerade®) daily for 7 days.
Study: NCT04016376
Drug: PVB Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
Study: NCT04016376
Drug: PECS-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor
Study: NCT04016376
Drug: Serratus
Normalized name: FUCUS SERRATUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior.
Study: NCT02520388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04170088
Drug: 0.9% Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline used for comparision of efficacy of tranexamic acid
Study: NCT01814865
Drug: Aromatase Inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg PO OD x 2 weeks
Study: NCT03897452
Drug: Fentanyl (5 microgram/ml) prediluted ampoules
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bolus; Fentanyl (5 microgram/ml) 0,5 microgram/kg (0.1 ml/kg) is administered over 1 min starting 3-5 min before the lighter skin breaking procedure.~Fentanyl (5 microgram/ml) 2 microgram/kg is administered over 10 min before the start of the more painful procedur ( pleura drainage or tracheal intubation).
Study: NCT01510119
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03756298
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine monotherapy (2,500mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
Study: NCT02245256
Drug: placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02410499
Drug: MLN1202 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN1202 placebo-matching solution for SC injection
Study: NCT03506412
Drug: Entresto™ 49Mg-51 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks
Study: NCT02410499
Drug: MLN1202
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN1202 solution for SC injection
Study: NCT02541071
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03068975
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive the Placebo Pill (post operative dose only) and will monitor for post operative ileus.
Study: NCT01382017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00076011
Drug: Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03533452
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection
Study: NCT01227941
Drug: MK-4827 + pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial evaluation of a 16-day dosing schedule: A loading dose of MK-4827 will be administered orally on Days 1-2 of the cycle and a maintenance dose daily on Days 3-16. Pegylated liposomal doxorubicin 40 mg/m\^2 will be administered intravenously on Day 3 of each cycle. The maintenance dose of MK-4827 will be escalated, until the maximum tolerated dose (MTD) is determined. If the maintenance dose is escalated above the loading dose, the loading dose will be escalated to a level equal to the maintenance dose, for the subsequent cycle. Other dosing schedules of MK-4827 may be explored, including 7-, 10-, 21- and 28-day schedules.
Study: NCT01227941
Drug: MK-4827 + pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-4827 will be administered according to one or two dose schedules as determined in Part A. Pegylated liposomal doxorubicin 40 mg/m\^2 will be administered intravenously on Day 3 of the cycle.
Study: NCT01928290
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01928290
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes